A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia
The purpose of this study is to evaluate the safety, tolerability and potential efficacy of IDH305 with standard treatments for newly diagnosed IDH1R132 mutant acute myeloid leukemia (AML).
Acute Myeloid Leukemia (AML)
DRUG: IDH305
Dose Limiting toxicities, (escalation only), 10 months|Number of patients with adverse events (AEs), 36 months
Area Under Curve (AUC), To characterize the PK profile of IDH305 with SOC medications (each Arm), 36 months|Maximum Plasma Concentration (Cmax), To characterize the PK profile of IDH305 with SOC medications (each Arm), 36 months|Time taken to reach maximum plasma concentration (Tmax), To characterize the PK profile of IDH305 with SOC medications (each Arm), 36 months|Complete remission rate (CRR), To characterize preliminary anti-tumor activity for each arm of the study. (Arm 1 and Arm 2), 36 months|Overall response rate (ORR), To characterize preliminary anti-tumor activity for each arm of the study. (Arm 1 and Arm 2), 36 months|Event free survival (EFS), To characterize preliminary anti-tumor activity for each arm of the study. (Arm 1 and Arm 2), 36 months
The purpose of this study is to evaluate the safety, tolerability and potential efficacy of IDH305 with standard treatments for newly diagnosed IDH1R132 mutant acute myeloid leukemia (AML).